235
Participants
Start Date
June 21, 2016
Primary Completion Date
October 12, 2021
Study Completion Date
October 12, 2021
BMS-986179
Specified dose on specified days
Nivolumab
Specified dose on specified days
rHuPH20
Specified dose on specified days
Local Institution - 0017, Sydney
Local Institution - 0019, Randwick
Local Institution - 0018, Melbourne
Local Institution - 0005, New York
Local Institution - 0033, Marseille
Local Institution - 0021, Marseille
Local Institution - 0023, Buffalo
Local Institution - 0020, Pittsburgh
Local Institution - 0001, Baltimore
Local Institution - 0008, Toulouse
Local Institution - 0004, Nashville
Local Institution - 0028, Chicago
Local Institution - 0009, Dallas
Local Institution - 0016, Freiburg im Breisgau
Local Institution - 0012, Napoli
Local Institution - 0015, Munich
Local Institution - 0007, Villejuif
Local Institution - 0022, Boston
Local Institution - 0003, Ottawa
Local Institution - 0002, Toronto
Local Institution - 0024, Montreal
Local Institution - 0014, Montreal
Local Institution - 0013, Padua
Local Institution - 0006, Amsterdam
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY